Celltrion And Pfizer Cement Victory On Infliximab

Janssen's Cell-Culture Media Patent Not Infringed By Inflectra/Remsima

 
• By Dean Rudge
  
Gavel
Celltrion and Pfizer have the backing of an appeals court for their biosimilar infliximab • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Legal & IP

More from Generics Bulletin